Novomax Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -30.69%
- Profit Growth -45.87%
- Ebitda -40.03%
- Net Worth 14.68%
- Total Assets -17.96%
About Novomax Pharma
Novomax Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 June 2012 and has a history of 12 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Lakhvinder Arora, Harpreet Arora, Rajan Chatterjee, and One other member serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2012PTC238218
-
Company No.
238218
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Jun 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Novomax Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harpreet Arora
|
Director | 28-Jun-2012 | Current |
|
Lakhvinder Arora
|
Director | 01-Jun-2014 | Current |
|
Rajan Chatterjee
|
Director | 01-Jun-2014 | Current |
|
Rajeev Anand
|
Director | 28-Jun-2012 | Current |
Financial Performance of Novomax Pharma.
Novomax Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 30.69% decrease. The company also saw a substantial fall in profitability, with a 45.87% decrease in profit. The company's net worth Soared by an impressive increase of 14.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novomax Pharma?
In 2020, Novomax Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Novopharm Life Sciences Private LimitedLakhvinder Arora, Harpreet Arora and 1 more are mutual person
-
M H Medicus Private Limited
Lakhvinder Arora, Harpreet Arora and 1 more are mutual person
-
Mex Pharma Private Limited
Lakhvinder Arora is a mutual person
-
Panchdeep Medi-Care Private Limited.
Lakhvinder Arora and Harpreet Arora are mutual person
-
Danica Pharma Private Limited
Harpreet Arora is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novomax Pharma?
Unlock and access historical data on people associated with Novomax Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novomax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novomax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
